EGFR (Epidermal Growth Factor Receptor) overexpression, driven by hypomethylation, activates oncogenic pathways such as RAS/RAF/MEK/ERK and PI3-K/Akt/mTOR, which promote tumor proliferation, survival, angiogenesis, and resistance to therapy (43). This evidence concerns the gene MTOR and neoplasm.